A phase 2, multicentre, randomised trial will evaluate the effect of 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).

Trial Profile

A phase 2, multicentre, randomised trial will evaluate the effect of 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs PSMA 617 (Primary) ; Cabazitaxel
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TheraP
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 06 Nov 2017 According to Endocyte media release, this trial is planned to initiate in Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top